PRESS RELEASE DUBLIN.

‘Today can be an exciting day for Allergan and our 30,000 employees around the world who have helped us reach this particular moment,’ saidBrent Saunders, President and CEO of Allergan. ‘By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our business within the pharmaceutical market and our placement as a dynamic new breed of organization – a innovator in Growth Pharma. Today, under one company identification and name, we lay out on a new path forwards, encouraging our employees around the world to be bold in how we think and action, to engage also to move to meet the needs of physicians quickly, customers and patients.For the study, Sweeney and colleagues assigned 790 men with prostate cancer randomly, average age 63, to chemotherapy plus hormone therapy or hormone therapy alone. As well as the survival benefit, men who received the combination of chemotherapy and hormone therapy saw their tumor remain dormant for a lot more than 20 months before it started to progress, compared with near 12 weeks among those who only received hormone therapy, researchers found. Sweeney said that relative unwanted effects of the chemotherapy were mild, in general. Fatigue, low white bloodstream cell count and disease were the most common side effects, the scholarly study said. One man died from an unfamiliar cause, though researchers said the death may have been because of the chemotherapy.